AptarGroup, Inc.
ATRHealthcareNASDAQMedical Instruments & Supplies · Last scanned May 29, 2026
Scan Results
Daily timeframeAptarGroup, Inc. designs and manufactures drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, fragrance, facial skincare, color cosmetics, personal. At a $7.40B market cap, AptarGroup, Inc. ranks as a mid-cap company within healthcare. The company operates through three segments: Pharma, Beauty, and Closures.
Market Cap
$7.40B
Beta
0.42
P/E (TTM)
19.90
P/E (Fwd)
18.49
EPS (TTM)
$5.83
EPS (Fwd)
$6.27
ROE
14.8%
ROA
6.6%
Cash
$229.5M
Total Debt
$1.44B
Free CF
$253.0M
52W Change
-26.8%
Annual Financials
Cash vs Debt
The company holds $229.5M in cash, though total debt stands at $1.44B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $253.0M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 14.8% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 6.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $3.32B to $3.78B.
The relatively low beta of 0.42 suggests ATR is a less volatile holding compared to the broader index. AptarGroup, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for AptarGroup, Inc. and its sector.